MyFinsight
Home
Blog
About
Net decrease in cash
and cash...
-$12,244K
(-11.21%↓ Y/Y)
Loss on
extinguishment of debt
-$11,683K
Share-based compensation
$2,895K
(-16.59%↓ Y/Y)
Prepaid expenses and
other assets
-$2,136K
(31.19%↑ Y/Y)
Amortization of debt issuance
costs and discounts
$1,767K
(-67.86%↓ Y/Y)
Issuance of warrants
under the purchase...
$916K
Inventories
-$706K
(-133.93%↓ Y/Y)
Accrued expenses and
other liabilities
$216K
(109.93%↑ Y/Y)
Depreciation, amortization,
and impairment
$136K
(-51.25%↓ Y/Y)
Other, net
-$43K
(-490.91%↓ Y/Y)
Proceeds from issuance of
long-term debt under the...
$54,337K
Proceeds from issuance of
warrants under the credit...
$663K
Proceeds from shares
issued under employee...
$70K
(40.00%↑ Y/Y)
Proceeds from exercise of
stock options, net
$26K
(271.43%↑ Y/Y)
Net cash used for
operating activities
-$9,441K
(69.85%↑ Y/Y)
Net cash provided by
financing activities
-$2,591K
(-112.61%↓ Y/Y)
Net cash used for
investing activities
-$212K
(12.40%↑ Y/Y)
Canceled cashflow
$20,498K
Canceled cashflow
$55,096K
Net loss
-$22,864K
(37.32%↑ Y/Y)
Repayment of debt
principal - 13.5 notes
$44,992K
Capital expenditures
$212K
(-12.40%↓ Y/Y)
Accounts payable
-$3,427K
(-316.62%↓ Y/Y)
Trade and other
receivables, net
$2,459K
(-45.06%↓ Y/Y)
something is missing
-$916K
Deferred revenue
-$273K
(-950.00%↓ Y/Y)
Premium paid to retire
debt - 13.5 notes
$3,887K
Payments for financing
costs
$3,449K
(24535.71%↑ Y/Y)
Payments for taxes on
share-based compensation,...
$3,241K
(348.89%↑ Y/Y)
Debt exit fee paid -
13.5 notes
$2,000K
Proceeds from common
stock issued under...
-$79K
Payments for lease
liabilities
$18K
Back
Back
Cash Flow
Aquestive Therapeutics, Inc. (AQST)
Aquestive Therapeutics, Inc. (AQST)
source: myfinsight.com